

Pharmacy Drug Policy Checklist

POLICY NAME Cerdelga (Eliglustat Tartrate) POLICY # 2435P

Criteria Company de la Comp	
Exclusion Criteria – Any of the following prevents coverage	
	2.1 Not used in combination with Zavesca, Elelyso, Cerezyme or VPRIV
	2.2 Patients whose CYP2D6 genotype cannot be determined or those who are ultra-rapid metabolizers (ultra- rapid metabolizers may not be able to achieve adequate concentrations of eliglustat to achieve a therapeutic effect)
Coverage Criteria	
	1.1 Diagnosis of non-neuropathic (type 1) Gaucher's disease confirmed by enzyme assay or gene testing
	1.2 CYP2D6 phenotype determination testing
	1.3 Age 18 years or older
	1.4 Ordered by a Geneticist or physician who is specialized in the treatment of Gaucher Disease